Me Today lifts FY26 revenue guidance by 14% on New Zealand and SE Asia growth

Me Today has raised its full-year revenue forecast to over NZD 7.4 million, driven by strong domestic sales and a new exclusive distribution deal in Southeast Asia. The nutritional supplements company also expects a 25% reduction in EBITDA loss, reflecting tighter cost control amid ongoing product innovation.

  • FY26 gross revenue guidance increased by 14% to exceed NZD 7.4 million
  • New Zealand sales surge with 113% growth in largest retail partner
  • Exclusive SE Asia distribution agreement signed covering four countries
  • NZD 1.1 million licence fee received from China partnership
  • EBITDA loss forecast reduced by 25% to less than NZD 1.6 million
An image related to Me Today Limited
Image © middle. Logo © respective owner.

Revenue upgrade driven by New Zealand market momentum

Me Today Limited (NZX:MEE) has boosted its full-year gross revenue guidance for FY26 to more than NZD 7.4 million, marking a 27% increase over FY25 and a 14% uplift on its February forecast. This upgrade primarily stems from robust sales growth in New Zealand, where the brand has expanded its shelf presence with its largest retail partner and launched 15 new products during the financial year.

Notably, retail scan data reveals a 113% increase in sales over the past 12 months at this key partner, attributed to a new in-store planogram introduced in March that enhances brand visibility. The product launches include the Potent Herbal liquid supplement range and several women’s wellness powders, marking Me Today’s first foray into powdered supplements.

Exclusive Southeast Asia deal opens new growth corridor

Internationally, Me Today has secured an exclusive distribution agreement covering Singapore, Malaysia, Thailand, and Vietnam. This five-year deal includes minimum sales targets and leverages an established distributor network across these markets. The brand’s initial launch is set for Singapore, with a major event planned for July following a visit by top-performing agents to New Zealand.

The company has already received an opening purchase order for ten products, with deliveries scheduled for May and June. While Singapore’s regulatory environment allows a swift market entry, Malaysia and other countries are expected to follow in 2027 once registration requirements are met.

China licence fee confirms growing international traction

Me Today’s partnership in China continues to bear fruit, with a NZD 1.1 million licence fee received for the year ending 31 March 2026. The fee is calculated as a percentage of Me Today product sales through the partner’s extensive network. The collaboration has expanded product offerings and broadened online promotion beyond the Douyin platform, reaching a wider consumer base in Mainland China.

Other markets and EBITDA improvement

Beyond Asia, Me Today maintains a presence in the USA, Japan, Ireland, and the UAE. In the USA, sales focus on Manuka honey products, generating NZD 1.04 million in orders so far this financial year, with additional deliveries pending. However, future growth in this market hinges on securing Manuka honey supply at suitable price and quality.

Financially, the company expects to reduce its operating EBITDA loss by 25% to less than NZD 1.6 million, improving on February’s guidance by NZD 100,000. This reflects a balancing act between revenue growth and continued investment in product development, brand building, and distribution capabilities.

Bottom Line?

Me Today’s upgraded guidance and strategic moves in Southeast Asia and China suggest momentum, but execution risks remain around regulatory approvals and supply chain constraints.

Questions in the middle?

  • How quickly will Me Today’s Southeast Asia expansion translate into sustained revenue growth beyond initial markets?
  • What impact will Manuka honey supply challenges have on the company’s US sales trajectory?
  • Can Me Today maintain EBITDA improvements while continuing to invest heavily in new product development and brand presence?